PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment.

IF 0.8 Q4 RESPIRATORY SYSTEM Turkish Thoracic Journal Pub Date : 2022-01-01 DOI:10.5152/TurkThoracJ.2021.21151
Pınar Gursoy, Burcu Çakar, Damla Gunenc, Deniz Nart, Akın Çınkooğlu, Nuran Katgı
{"title":"PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment.","authors":"Pınar Gursoy,&nbsp;Burcu Çakar,&nbsp;Damla Gunenc,&nbsp;Deniz Nart,&nbsp;Akın Çınkooğlu,&nbsp;Nuran Katgı","doi":"10.5152/TurkThoracJ.2021.21151","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To show the effect of programmed cell death protein-1ligand (PDL-1) level on survival times in patients with metastatic non-small cell lung cancer (mNSCLC) receiving chemotherapy, to determine the relationship between PDL-1 level, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).</p><p><strong>Material and methods: </strong>The data of 158 patients who received chemotherapy for mNSCLC were evaluated retrospectively. Clinical and demographic data, PDL-1 expression levels and follow-up periods of the patients were recorded. The patients were divided into 2 groups according to PDL-1 levels.</p><p><strong>Results: </strong>In all patients, progression free survival (PFS) was 5.6 months and overall survival (OS) was 18.8 months. Patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.038). In the gemcitabine and taxane groups, patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.047). There was a significant correlation between NLR and PDL-1 levels. In the groups with high PDL-1, patients with low NLR levels had higher OS than patients with high NLR level (p:0.043). Also, there was a significant difference between the OS patients with low and high PLR levels (p:0.520).</p><p><strong>Conclusion: </strong>In patients with mNSCLC whose PDL-1 levels and NLR levels are low, immunogenic chemotherapies such as gemcitabine and taxane can be tried as an alternative treatment.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"23 1","pages":"45-51"},"PeriodicalIF":0.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/7d/ttj-23-1-45.PMC9450090.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Thoracic Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/TurkThoracJ.2021.21151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To show the effect of programmed cell death protein-1ligand (PDL-1) level on survival times in patients with metastatic non-small cell lung cancer (mNSCLC) receiving chemotherapy, to determine the relationship between PDL-1 level, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).

Material and methods: The data of 158 patients who received chemotherapy for mNSCLC were evaluated retrospectively. Clinical and demographic data, PDL-1 expression levels and follow-up periods of the patients were recorded. The patients were divided into 2 groups according to PDL-1 levels.

Results: In all patients, progression free survival (PFS) was 5.6 months and overall survival (OS) was 18.8 months. Patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.038). In the gemcitabine and taxane groups, patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.047). There was a significant correlation between NLR and PDL-1 levels. In the groups with high PDL-1, patients with low NLR levels had higher OS than patients with high NLR level (p:0.043). Also, there was a significant difference between the OS patients with low and high PLR levels (p:0.520).

Conclusion: In patients with mNSCLC whose PDL-1 levels and NLR levels are low, immunogenic chemotherapies such as gemcitabine and taxane can be tried as an alternative treatment.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受化疗作为一线治疗的转移性非小细胞肺癌患者的PDL-1表达和生存率。
目的:探讨程序性细胞死亡蛋白-1配体(PDL-1)水平对转移性非小细胞肺癌(mNSCLC)化疗患者生存时间的影响,探讨PDL-1水平与中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)的关系。材料与方法:回顾性分析158例小细胞肺癌化疗患者的资料。记录患者的临床及人口学资料、PDL-1表达水平及随访时间。根据PDL-1水平将患者分为两组。结果:所有患者无进展生存期(PFS)为5.6个月,总生存期(OS)为18.8个月。低PDL-1患者的PFS较高PDL-1患者长(p:0.038)。在吉西他滨和紫杉烷组中,低PDL-1的患者比高PDL-1的患者的PFS更长(p:0.047)。NLR与PDL-1水平有显著相关性。在高PDL-1组中,低NLR患者的OS高于高NLR患者(p:0.043)。此外,低PLR水平和高PLR水平的OS患者之间存在显著差异(p:0.520)。结论:对于PDL-1水平和NLR水平较低的小细胞肺癌患者,可尝试免疫原性化疗如吉西他滨和紫杉烷作为替代治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Turkish Thoracic Journal
Turkish Thoracic Journal Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.40
自引率
11.10%
发文量
2
期刊介绍: Turkish Thoracic Journal (Turk Thorac J) is the double-blind, peer-reviewed, open access, international publication organ of Turkish Thoracic Society. The journal is a quarterly publication, published on January, April, July, and October and its publication language is English. Turkish Thoracic Journal started its publication life following the merger of two journals which were published under the titles “Turkish Respiratory Journal” and “Toraks Journal” until 2007. Archives of both journals were passed on to the Turkish Thoracic Journal. The aim of the journal is to convey scientific developments and to create a dynamic discussion platform about pulmonary diseases. With this intent, the journal accepts articles from all related scientific areas that address adult and pediatric pulmonary diseases, as well as thoracic imaging, environmental and occupational disorders, intensive care, sleep disorders and thoracic surgery. Clinical and research articles, reviews, statements of agreement or disagreement on controversial issues, national and international consensus reports, abstracts and comments of important international articles, interesting case reports, writings related to clinical and practical applications, letters to the editor, and editorials are accepted.
期刊最新文献
Attitude and Practice Toward Use of Cigarettes and Electronic Cigarettes Among Pregnant Women: A Questionnaire-Based Survey. Should Pneumothorax Developing During the Recovery Period After COVID-19 in Patients with Previously Healthy Lungs be Considered a Primary Spontaneous Pneumothorax or a Secondary Spontaneous Pneumothorax? A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab. Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations. The Use of High-Flow Nasal Oxygen Therapy in the Management of Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Feasibility Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1